caa a22 4500 397590768 CHVBK 20180308164938.0 cr unu---uuuuu 161202e199606 xx s 000 0 eng 10.1093/jac/37.suppl_C.37 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_C.37 The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension [Elektronische Daten] [G. Foulds, D. R. Luke, R. Teng, S. A. Willavize, H. Friedman, W. J. Curatolo] Present product labelling indicates that azithromycin capsules should not be taken with food. However, three recent studies demonstrated that food does not significantly decrease the bioavailabilities of three new formulations of azithromycin (250 mg tablets, 1000 mg sachet, 500 mg paediatric suspension). With a 500 mg dosage, the mean relative bioavailability of azithromycin following ingestion of a standard high-fat breakfast was 96% when administered as two 250 mg tablets and 113% when administered as a suspension. The mean relative bioavailability of a 1000 mg sachet was 112%. The absolute bioavailability of the sachet formulation, relative to a 1 h iv infusion of 1000 mg, was 44%. Thus, azithromycin tablets, suspension and sachet may be given without regard to meals, further enhancing the convenience of once-daily, short-duration dosing regimens. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Foulds G. Drug Metabolism, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut Luke D. R. Clinical Research, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut Teng R. Drug Metabolism, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut Willavize S. A. Biometrics Departments, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut Friedman H. Clinical Pharmacology, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut Curatolo W. J. Pharmaceutical Research and Development, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 37-44 0305-7453 37<37 1996 37 jac https://doi.org/10.1093/jac/37.suppl_C.37 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_C.37 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Foulds G. Drug Metabolism, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut NATIONALLICENCE 700 1- Luke D. R. Clinical Research, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut NATIONALLICENCE 700 1- Teng R. Drug Metabolism, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut NATIONALLICENCE 700 1- Willavize S. A. Biometrics Departments, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut NATIONALLICENCE 700 1- Friedman H. Clinical Pharmacology, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut NATIONALLICENCE 700 1- Curatolo W. J. Pharmaceutical Research and Development, Central Research Division Pfizer Inc., Grown, CT 06340, USA aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 37-44 0305-7453 37<37 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford